---
layout: default
title: Thymol
parent: 僅模型預測 (L5)
nav_order: 647
evidence_level: L5
indication_count: 10
---

# Thymol
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Thymol: From Antiseptic Use to Interventricular Septum Aneurysm

## One-Sentence Summary

Thymol (DrugBank DB02513) is a monoterpenol phenol traditionally used as an antiseptic/anti-inflammatory ingredient in oral and topical products; no original indication text is recorded in the current registry data.
The TxGNN model predicts it may be effective for **Interventricular Septum Aneurysm**, but this is currently supported by **0 clinical trials** and **0 publications** — the prediction is a pure model output with no corroborating evidence.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not specified in registry data (Thymol is generally used as an antiseptic/anti-inflammatory agent in oral and topical products) |
| Predicted New Indication | Interventricular Septum Aneurysm |
| TxGNN Prediction Score | 99.25% |
| Evidence Level | L5 (model prediction only, no supporting studies) |
| Malaysia Market Status | ✓ Marketed |
| Number of Registrations | 21 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Based on known information, thymol is a monoterpene phenol derived from thyme oil, with well-documented antimicrobial, antioxidant, and anti-inflammatory activity used in antiseptic and mouth/throat care products. None of this known pharmacology involves cardiac structural remodeling, valvular tissue biology, or septal wall integrity pathways.

Interventricular septum aneurysm is a structural cardiac abnormality (localized bulging/thinning of the septal wall), typically congenital or post-infarction in origin. There is no known mechanistic pathway — antimicrobial, antioxidant, or anti-inflammatory — by which thymol would be expected to influence cardiac structural pathology. The TxGNN score is driven by knowledge-graph similarity rather than any pharmacological rationale, and the evidence pack itself found zero clinical trials, zero ICTRP trials, and zero PubMed publications linking thymol to this disease.

Because both the mechanistic link and the literature/trial base are absent, this prediction should be treated as a graph-similarity signal only, not as an actionable repurposing hypothesis at this time.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Malaysia Market Information

The evidence pack confirms Thymol holds **21 active registrations** under "已上市" (Marketed) status in Malaysia, but no license number, product name, dosage form, or approved-indication text was returned for any of the sampled entries. Registry detail retrieval needs to be re-run against the NPRA source to populate this table.

---

## Other Candidates Screened (Same Batch)

This evidence pack (`TW-DB02513-multi`) screened the top 10 TxGNN-ranked indications for Thymol. All 10 were scored L5 / Hold:

| Rank | Predicted Indication | Score | Notes |
|------|----------------------|-------|-------|
| 1 | Interventricular septum aneurysm | 99.25% | No mechanistic link, no evidence |
| 2 | Pulmonary valve disease | 99.17% | No mechanistic link, no evidence |
| 3 | Laubry-Pezzi syndrome | 99.17% | Structural congenital defect, not druggable target |
| 4 | Genetic syndromic Pierre Robin syndrome | 99.15% | Developmental/genetic disorder, no relevant MOA |
| 5 | Orofacial clefting syndrome | 99.15% | Developmental disorder, no relevant MOA |
| 6 | Partial deletion of chromosome 22q | 99.14% | Chromosomal disorder, not druggable |
| 7 | Pierre Robin syndrome (chromosomal anomaly) | 99.13% | Genetic disorder, no relevant MOA |
| 8 | Disorder of fucoglycosan synthesis | 99.13% | 20 literature hits, but manual review found **none** address this disease — all are general thymol pharmacology papers (antioxidant, anti-inflammatory, endometriosis, sepsis, etc.). Assessed as a disease-vocabulary mapping artifact, not real evidence. |
| 9 | Partial deletion of chromosome 7q | 99.13% | Chromosomal disorder, not druggable |
| 10 | Jeune syndrome with situs inversus | 99.12% | Ciliopathy, no relevant MOA |

None of the 10 candidates in this batch clear even the lowest evidence bar (L4). Rank 8 is worth flagging specifically to prevent its literature *count* being mistaken for literature *relevance* in downstream triage.

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The prediction is TxGNN model output only (L5), with zero clinical trials, zero ICTRP trials, and zero literature support, and the rationale text itself concludes there is no known mechanistic link between thymol's antiseptic/anti-inflammatory pharmacology and interventricular septum aneurysm (a structural cardiac defect). This does not meet the evidence threshold to advance to safety screening (S1).

**To proceed, the following is needed:**
- Confirmed mechanism of action (MOA) data for Thymol from DrugBank or primary literature
- NPRA-sourced label data: key warnings, contraindications, and approved indication text (currently all missing/blocking gaps)
- Any preclinical or mechanistic study directly linking thymol to cardiac structural pathology, before this candidate is reconsidered
- If pursuing candidate #8 (fucoglycosan synthesis disorder) further, re-run literature search with disease-specific MeSH terms rather than drug-name-only matching to rule out the mapping artifact
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

